Division of Nephrology and Hypertension, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois2Center for Translational Metabolism and Health, Institute of Public Health and Medicine, Northwestern University Feinbe.
Center for Translational Metabolism and Health, Institute of Public Health and Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
JAMA Cardiol. 2016 Aug 1;1(5):548-56. doi: 10.1001/jamacardio.2016.1445.
Levels of fibroblast growth factor 23 (FGF23) are elevated in chronic kidney disease (CKD) and strongly associated with left ventricular hypertrophy, heart failure, and death. Whether FGF23 is an independent risk factor for atrial fibrillation in CKD is unknown.
To investigate the association of FGF23 with atrial fibrillation in CKD.
DESIGN, SETTING, AND PARTICIPANTS: Prospective cohort study of 3876 individuals with mild to severe CKD who enrolled in the Chronic Renal Insufficiency Cohort Study between June 19, 2003, and September 3, 2008, and were followed up through March 31, 2013.
Baseline plasma FGF23 levels.
Prevalent and incident atrial fibrillation.
The study cohort comprised 3876 participants. Their mean (SD) age was 57.7 (11.0) years, and 44.8% (1736 of 3876) were female. Elevated FGF23 levels were independently associated with increased odds of prevalent atrial fibrillation (n = 660) after adjustment for cardiovascular and CKD-specific factors (odds ratio of highest vs lowest FGF23 quartile, 2.30; 95% CI, 1.69-3.13; P < .001 for linear trend across quartiles). During a median follow-up of 7.6 years (interquartile range, 6.3-8.6 years), 247 of the 3216 participants who were at risk developed incident atrial fibrillation (11.9 events per 1000 person-years). In fully adjusted models, elevated FGF23 was independently associated with increased risk of incident atrial fibrillation after adjustment for demographic, cardiovascular, and CKD-specific factors, and other markers of mineral metabolism (hazard ratio of highest vs lowest FGF23 quartile, 1.59; 95% CI, 1.00-2.53; P = .02 for linear trend across quartiles). The results were unchanged when further adjusted for ejection fraction, but individual adjustments for left ventricular mass index, left atrial area, and interim heart failure events partially attenuated the association of elevated FGF23 with incident atrial fibrillation.
Elevated FGF23 is independently associated with prevalent and incident atrial fibrillation in patients with mild to severe CKD. The effect may be partially mediated through a diastolic dysfunction pathway that includes left ventricular hypertrophy, atrial enlargement, and heart failure events.
成纤维细胞生长因子 23(FGF23)水平在慢性肾脏病(CKD)中升高,与左心室肥厚、心力衰竭和死亡密切相关。FGF23 是否是 CKD 中心房颤动的独立危险因素尚不清楚。
研究 FGF23 与 CKD 中心房颤动的关系。
设计、地点和参与者:这是一项前瞻性队列研究,纳入了 3876 名轻度至重度 CKD 患者,他们于 2003 年 6 月 19 日至 2008 年 9 月 3 日参加了慢性肾功能不全队列研究,并在 2013 年 3 月 31 日之前接受了随访。
基线时的血浆 FGF23 水平。
现患和新发心房颤动。
研究队列包括 3876 名参与者。他们的平均(SD)年龄为 57.7(11.0)岁,44.8%(1736/3876)为女性。在调整心血管和 CKD 特异性因素后,升高的 FGF23 水平与现患心房颤动的几率增加独立相关(最高四分位与最低四分位相比,比值比为 2.30;95%置信区间,1.69-3.13;P<0.001 呈四分位趋势)。在中位随访 7.6 年(四分位间距,6.3-8.6 年)期间,3216 名有风险的参与者中有 247 名发生了新发心房颤动(每 1000 人年 11.9 例)。在充分调整的模型中,升高的 FGF23 与经过调整后的人口统计学、心血管和 CKD 特异性因素以及其他矿物质代谢标志物后,新发心房颤动的风险增加独立相关(最高四分位与最低四分位相比,风险比为 1.59;95%置信区间,1.00-2.53;P=0.02 呈四分位趋势)。当进一步调整射血分数时,结果保持不变,但对左心室质量指数、左心房面积和中期心力衰竭事件的单独调整部分减弱了升高的 FGF23 与新发心房颤动之间的关联。
升高的 FGF23 与轻度至重度 CKD 患者的现患和新发心房颤动独立相关。该效应可能部分通过包括左心室肥厚、心房扩大和心力衰竭事件的舒张功能障碍途径介导。